EMERGING ROLE OF NRF2 AS A POTENTIAL THERAPEUTIC TARGET FOR CARDIOVASCULAR DISEASES-Reference-Cited by-同舟云学术

EMERGING ROLE OF NRF2 AS A POTENTIAL THERAPEUTIC TARGET FOR CARDIOVASCULAR DISEASES

Published:2020-09-01 Issue: Volume: Page:1-9
ISSN:
Container-title:INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
language:en
Short-container-title:ijsr

Author:

Shergill Gagandeep Singh¹,Sarotra Pooja²,Kadam Prince¹,Kapoor Sumir¹,Singh Arshbir¹,Rana Nishant¹

Affiliation:

1. Researcher, Department of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.

2. Assistant Professor, Department of Biochemistry, Pt. Jawahar Lal Nehru Government Medical College and Hospital, Chamba, Himachal Pradesh, India.

Abstract

Nuclear factor erythroid 2-like 2 (Nrf2) is a transcription factor playing a big part in dynamic control of the antioxidant and cytoprotective gene system via activating the antioxidant response element (ARE) expression. Several Nrf2-targeted enzymes are essential for cardiovascular disease pathogenesis and are closely correlated with atherosclerosis, myocardial ischemia, diabetic cardiomyopathy, and congestive heart failure; moreover, they function as sensitive and precise markers to represent the ventricular function in heart failure patients. Activation of Nrf2 offers cardioprotection by synchronized up-regulation of the processes of antioxidative, anti-inflammatory, and autophagy. Thus, it may be worth examining the possible role of the Nrf2 signaling in cardioprotection. This review will encapsulate the present information about the structure, regulation, and participation of Nrf2 in various cardiovascular disorders and related complications like diabetic cardiomyopathy, hypertension, and obesity. A particular focus is put on Nrf2 inducers, which are potentially attractive therapeutic candidates for several cardiovascular disorders.

Publisher

World Wide Journals

Reference152 articles.

1. Araujo, J. A., Zhang, M., & Yin, F. (2012). Heme Oxygenase-1, Oxidation, Inflammation, and Atherosclerosis. Frontiers in Pharmacology, 3. https://doi.org/10.3389/fphar.2012.00119

2. 2. Avogaro, A., Albiero, M., Menegazzo, L., de Kreutzenberg, S., & Fadini, G. P. (2011). Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms. Diabetes Care, 34(Supplement_2), S285–S290. https://doi.org/10.2337/dc11-s239

3. 3. Bai, Y., Cui, W., Xin, Y., Miao, X., Barati, M. T., Zhang, C., Chen, Q., Tan, Y., Cui, T., Zheng, Y., & Cai, L. (2013). Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. Journal of Molecular and Cellular Cardiology, 57, 82–95. https://doi.org/10.1016/j.yjmcc.2013.01.008

4. 4. BALOGUN, E., HOQUE, M., GONG, P., KILLEEN, E., GREEN, C. J., FORESTI, R., ALAM, J., & MOTTERLINI, R. (2003). Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochemical Journal, 371(3), 887–895. https://doi.org/10.1042/bj20021619

5. 5. Banning, A., Deubel, S., Kluth, D., Zhou, Z., & Brigelius-Flohé, R. (2005). The GI-GPx Gene Is a Target for Nrf2. Molecular and Cellular Biology, 25(12), 4914–4923. https://doi.org/10.1128/MCB.25.12.4914-4923.2005